EPO and myelodysplastic syndrome: Information on therapy was available for MDS/MPN-RS-T patients in the Mayo cohort (n = 78); 44 (56%) were treated with erythropoietin stimulating agents, 16 (21%) lenalidomide, 4 (5%) investigational agents, while 1 each was treated with danazol, hydroyxurea, and splenectomy, respectively.